Case Report: Management of recurrent UTI with tigecycline in a kidney transplant recipient

TL;DR

A kidney transplant patient with recurring antibiotic-resistant UTIs was successfully treated with tigecycline, despite it not being a typical urinary antibiotic.

Contribution

Demonstrates tigecycline's effectiveness in treating multidrug-resistant UTIs in immunocompromised patients when standard treatments fail.

Findings

Tigecycline successfully managed recurrent UTIs caused by MDR Klebsiella pneumoniae in a kidney transplant recipient.

Standard antibiotics like fosfomycin and meropenem failed to resolve persistent infections.

Tigecycline provided a crucial therapeutic option in the context of antibiotic resistance.

Abstract

This case report describes a 37-year-old man who underwent renal transplantation and subsequently developed complicated recurrent urinary tract infections (UTIs) caused by multidrug-resistant (MDR) Klebsiella pneumoniae. Despite initial treatment with fosfomycin and meropenem, the patient experienced persistent UTIs, leading to multiple hospitalizations. The management of these recurrent infections eventually required the use of tigecycline. Although tigecycline is not typically considered a urinary antibiotic owing to its limited urinary excretion, it was successfully employed in this case to manage the recurrent infections. The patient was treated with tigecycline for several episodes of UTI, which provided a crucial therapeutic option in the context of antibiotic resistance. This case underscores the challenges of managing recurrent MDR UTIs in immunocompromised patients and highlights tigecycline as an effective treatment strategy when standard therapies fail.